Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13704094 | 0.92 | MEN1 (0.57) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13704056 | 0.92 | MEN1 (0.57) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13704098 | 0.92 | MEN1 (0.57) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4289956 | 0.89 | MEN1 (0.63) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13704097 | 0.88 | MEN1 (0.63) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13704095 | 0.88 | MEN1 (0.63) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13704096 | 0.88 | MEN1 (0.63) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4288741 | 0.85 | MEN1 (0.57) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL13704066 | 0.83 | MEN1 (0.72) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL4294419 | 0.83 | MEN1 (0.62) | MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| WO-2007026024-A2 | BENZODIAZEPINES AS HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | MEN1 4829/4885KMT2A 1440/4885KDM4E 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.